Please assess the completion status of the following clinical trial:

Trial Title: Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Is 18 to 70 years old~* Is male, or is female and meets all the following criteria:~  1. Not breastfeeding~ 2. Negative pregnancy test result and, if of childbearing potential, must practice and be willing to continue to practice appropriate birth control~* Has been diagnosed with type 1 diabetes mellitus for at least 1 year and not achieving glycemic goal while on MDI of insulin~* Has HbA1c between 7.0% and 9.0%~* Has been on MDI of regular insulin, at a dose not to exceed 10 units/breakfast for at least 3 months or has been on continuous subcutaneous insulin infusion (CSII), at a dose not to exceed 10 units/breakfast, for at least 3 months and is willing to switch to an MDI insulin regimen for 1 day prior to enrollment and through the study~* Has a body mass index (BMI) \<30 kg/m2~Exclusion Criteria:~* Has experienced recurrent severe hypoglycemia requiring assistance within 6 months before Visit 1 Screening~* Has a history of hypoglycemia unawareness~* Has a confirmed diagnosis of gastroparesis~* Has been treated, is currently being treated, or is expected to require or undergo treatment with the following medications:~  1. Any antihyperglycemic agent other than insulin~ 2. Drugs that directly affect gastrointestinal motility (e.g., anticholinergic agents such as atropine)~ 3. Drugs that slow the intestinal absorption of nutrients (e.g., α-glucosidase inhibitors.~* Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:~  1. Hepatic disease~ 2. Renal disease~ 3. Gastrointestinal disease~ 4. Pulmonary disease~ 5. Organ transplantation~ 6. Chronic infection (e.g., tuberculosis, human immunodeficiency virus, hepatitis B virus, or hepatitis C virus)~* Is currently treated or has been previously treated with SYMLIN/pramlintide or has participated in a SYMLIN/pramlintide clinical study within 3 months of Visit 1 (Screening).~* Has any clinically significant laboratory findings or medical history that may affect successful completion of the study and/or personal well-being~* Has donated blood within 2 months or is planning to donate blood during the study.~* Has had a major surgery or a blood transfusion within 2 months~* Has received any investigational drug within 1 month~* Has known allergies or hypersensitivity to any component of study treatment.~* Is an immediate family member of personnel directly affiliated with the study at the clinical study site, or is directly affiliated with the study at the clinical study site.~* Is employed by Amylin Pharmaceuticals, Inc (Amylin) (that is an employee, temporary contract worker, or designee responsible for the conduct of the study).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pramlintide 6 mcg per unit of insulin dose (Type: EXPERIMENTAL): The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 6 mcg for each unit of insulin.
- Pramlintide 9 mcg per unit of insulin dose (Type: EXPERIMENTAL): The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 9 mcg for each unit of insulin.
- Pramlintide 12 mcg per unit of insulin dose (Type: EXPERIMENTAL): The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 12 mcg for each unit of insulin.
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).